Heart Attack

JERAYGO (aprocitentan) recommended for approval in Europe for the treatment of resistant hypertensionJERAYGO (aprocitentan) recommended for approval in Europe for the treatment of resistant hypertension

JERAYGO (aprocitentan) recommended for approval in Europe for the treatment of resistant hypertension

Ad hoc announcement pursuant to Art. 53 LR Idorsia receives a positive opinion from the Committee for Medicinal Products for…

1 year ago
New Study Shows 94% Reduction in COVID-19 Cases in a Residential Healthcare Facility With ActivePure TechnologyNew Study Shows 94% Reduction in COVID-19 Cases in a Residential Healthcare Facility With ActivePure Technology

New Study Shows 94% Reduction in COVID-19 Cases in a Residential Healthcare Facility With ActivePure Technology

Technology offers timely and cost-efficient infection prevention solution for long-term care amidst industry-wide labor shortagesDALLAS, TX / ACCESSWIRE / April…

1 year ago
Exponential Health Partners with Cardio Diagnostics to Elevate Cardiovascular Disease Prevention in MichiganExponential Health Partners with Cardio Diagnostics to Elevate Cardiovascular Disease Prevention in Michigan

Exponential Health Partners with Cardio Diagnostics to Elevate Cardiovascular Disease Prevention in Michigan

Exponential Health, an innovative concierge medicine practice in Michigan, adopts Cardio Diagnostics' AI-driven epigenetic-genetic tests, marking a new era in…

1 year ago
Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24

Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24

Data Further Advance Understanding of VASCEPA®/VAZKEPA® Potential Mechanism of ActionDUBLIN, Ireland and BRIDGEWATER, N.J., April 08, 2024 (GLOBE NEWSWIRE) --…

1 year ago
New Novartis data show early addition of twice-yearly* Leqvio® (inclisiran) following maximally tolerated statin therapy significantly reduces LDL-C in ASCVD patients in real-world settingNew Novartis data show early addition of twice-yearly* Leqvio® (inclisiran) following maximally tolerated statin therapy significantly reduces LDL-C in ASCVD patients in real-world setting

New Novartis data show early addition of twice-yearly* Leqvio® (inclisiran) following maximally tolerated statin therapy significantly reduces LDL-C in ASCVD patients in real-world setting

V-INITIATE trial demonstrates that early initiation with Leqvio, prior to guideline-recommended ezetimibe, for ASCVD patients unable to achieve LDL-C goal…

1 year ago
New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient SubgroupsNew REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups

New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups

-- Findings Presented on VASCEPA/VAZKEPA Utility in REDUCE-IT Patient Subgroups by Baseline High/Low Lp(a), LDL-C Levels -- -- Lp(a) Results…

1 year ago
Cantargia Publishes Data Highlighting the Potential of CAN10 in AtherosclerosisCantargia Publishes Data Highlighting the Potential of CAN10 in Atherosclerosis

Cantargia Publishes Data Highlighting the Potential of CAN10 in Atherosclerosis

LUND, SWEDEN / ACCESSWIRE / April 2, 2024 / Cantargia (STO:CANTA) Cantargia (Cantargia AB; Nasdaq Stockholm:CANTA) today reported publication of…

1 year ago
Research Evaluating Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the American College of Cardiology’s (ACC) Annual Scientific Session & ExpoResearch Evaluating Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the American College of Cardiology’s (ACC) Annual Scientific Session & Expo

Research Evaluating Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the American College of Cardiology’s (ACC) Annual Scientific Session & Expo

-- Subgroup Analyses from REDUCE-IT® and Mechanistic Data on Icosapent Ethyl(IPE)/Eicosapentaenoic Acid (EPA) Featured at the Meeting --    DUBLIN,…

1 year ago
Tonix Pharmaceuticals Announces Transition to Fully Integrated Biopharmaceutical Company Expected on April 1, 2024Tonix Pharmaceuticals Announces Transition to Fully Integrated Biopharmaceutical Company Expected on April 1, 2024

Tonix Pharmaceuticals Announces Transition to Fully Integrated Biopharmaceutical Company Expected on April 1, 2024

Zembrace® SymTouch® and Tosymra® will be marketed by Tonix Medicines, Tonix’s wholly-owned commercial subsidiary Commercial capabilities prepare Tonix for the…

1 year ago
What Are The Symptoms to Watch For Of A Heart Attack For Men And For WomanWhat Are The Symptoms to Watch For Of A Heart Attack For Men And For Woman

What Are The Symptoms to Watch For Of A Heart Attack For Men And For Woman

A heart attack, medically known as myocardial infarction, occurs when the blood supply to the heart is blocked, often by…

1 year ago